YelenaNovikMDFACP

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Professor, Medicine, New York University School of Medicine

Join to view full profile

Dr. Novik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Novik's full profile

Already have an account?

Office
160 E 34th St
# Nyu
New York, NY 10016
Phone+1 212-731-5350

Fax+1 212-731-5574

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1995 - 1996
Jacobi Medical Center/Albert Einstein College of MedicineFellowship, Hematology and Medical Oncology, 1993 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1990 - 1993
Moscow State University of Medicine and DentistryClass of 1988

Certifications & Licensure

NY State Medical License 1994 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACP) American College of Physicians, 2001
NY Superdoctors

Clinical Trials

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 2003 Mar 01
Completed
Phase 2
Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer Start of enrollment: 2008 Jun 01
Terminated
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Start of enrollment: 2010 May 26
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer Start of enrollment: 2009 Mar 06
Completed
Phase 1, Phase 2
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
Completed
Phase 1, Phase 2
Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

15 citations
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri
Breast Cancer Research and Treatment. 2018-02-01
156 citations
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer
Sylvia Adams, Lina Kozhaya, Frank Martiniuk, Tze-Chiang Meng, Luis Chiriboga
Clinical Cancer Research. 2012-12-15
34 citations
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Hum...
Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach
Journal of Clinical Oncology. 2023-08-20

Press Mentions

Clinical Challenge: Adjuvant Options for HR-Positive, HER2-Negative Breast CancerJune 15th, 2021
To Host State of the Science Summit™ on Breast CancerJune 14th, 2018
NYU Langone Health in the News—Monday, April 29, 2024April 30th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow

Other Languages

French, Russian